The PD-1/PD-L1 Axis and Co-signaling Networks: Orchestrating T Cell Responses in Cancer and Autoimmunity
Resource:https://www.globecancer.com/azzx/show.php?itemid=15812
>> Scroll to view
| Drug Strategy | Strategy Type | Representative Drugs / Regimens | Core Mechanism / Objective |
|---|---|---|---|
|
PD-L1-targeting ADC
|
ADC
|
1. PD-L1 ADC: Henlius HLX43
2. PD-L1/αvβ6 integrin BsADC: Alphamab JSKN022
|
1. Target PD-L1 and achieve targeted killing through the cytotoxic payload of ADC
2. Dual targeting of PD-L1 and αvβ6 integrin to enhance tumor targeting and killing efficacy
|
|
PD-1 Plus: BsAb
|
Immune Escape Inhibition + Anti-angiogenesis
|
Simultaneously block PD-1-mediated immune escape signals, inhibit VEGF-mediated tumor angiogenesis, improve the tumor microenvironment, and enhance immunotherapeutic efficacy.
|
|
|
Immune Escape Inhibition + Immune Agonism
|
While blocking immune escape, activate immune effector cells such as T cells through the IL-2/4-1BB pathway to overcome immunotherapy resistance.
|
||
|
Multiple Immune Escape Inhibition
|
Simultaneously block multiple immune checkpoint pathways including PD-1, TIGIT, and CTLA-4 to strengthen the inhibition of immune escape.
|
||
|
Combination of PD-1/PD-L1 Inhibitor and ADC
|
Combination Therapy
|
Leverage the targeted killing effect of ADC and the immune activation function of PD-1/PD-L1 inhibitor to achieve synergistic antitumor effect and improve treatment response.
|
Human PD-L1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 98% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human PD-L1, His Tag (Cat. No. PD1-H5229) is more than 90% and the molecular weight of this protein is around 30-50kDa verified by SEC-MALS.
Request Report
Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 2 μg/mL (100 μL/well) can bind Human PD-L2, Mouse IgG1 Fc Tag (Cat. No. PD2-H52A5) with a linear range of 10-156 ng/mL (Routinely tested).
Request Protocol
Human PD-1, Fc Tag (Cat. No. PD1-H5257) captured on CM5 chip via anti-human IgG Fc antibody, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 3.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Request Protocol
Loaded Human PD-1, Fc Tag, low endotoxin (Cat. No. PD1-H5257) on Protein A Biosensor, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 5.3 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).
Request Protocol
Immobilized cell surface PD-1 (5x104 of cells per well) can bind Human PD-L1, Fc Tag (Cat. No. PD1-H5258) with an EC50 of 0.029 μg/mL (Routinely tested).
Request Protocol
Immobilized Biotinylated Human PD-L1, Avitag,His Tag (Cat. No. PD1-H82E5) at 1 μg/mL (100 μL/well) on Streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate, can bind Anti-PD-L1 MAb, Human IgG1 with a linear range of 0.2-3 ng/mL (Routinely tested).
Request Protocol
Anti-Human PD-L1 Mab (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human PD-L1, His Tag (Cat. No. PD1-H5229) with an affinity constant of 0.286 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Request Protocol
Immobilized Human PD-1, His Tag (Cat. No. PD1-H5221) at 5 μg/mL, add increasing concentrations of Cadonilimab (PD-1 x CTLA-4 bispecific antibody) and then add Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.99 ng/mL (Routinely tested).
Request Protocol
Immobilized Human VEGF165, His Tag (Cat. No. VE5-H5248) at 2 μg/mL, add increasing concentrations of Ivonescimab and then add Biotinylated Human PD-1 Protein, Avitag,His Tag (Cat. No. PD1-H82E4) at 2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 2.17 ng/mL (Routinely tested).
Flow Cytometry assay shows that Human PD-1 Protein, Fc Tag (Cat. No. PD1-H5257) can bind to 293 cell overexpressing human PD-L1. The concentration of PD-1 used is 1 μg/mL (Routinely tested).
Request Protocol
FACS analysis shows that the binding of Human PD-L1, Fc Tag (Cat. No. PD1-H5258) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing Anti-PD-L1 antibody. The concentration of PD-L1 used is 10 μg/mL. The IC50 is 12.92 μg/mL (Routinely tested).
Request Protocol
The Human PD-1 / PD-L1 Inhibitor Screening Kit (TR-FRET) (Cat. No. FRT-P019) is suitable for the detection of PD1/PD-L1 inhibitors. It shows that both Atezolizumab, Nofazinlimab and Pembrolizumab exhibit good inhibitory activity in this TR-FRET competition assay.
Request Protocol
Serial dilutions of Anti-PD-L1 Neutralizing antibody (Cat. No. EP133) (1:1 serial dilution, from 2 μg/mL to 0.015625μg/mL) was added into PD-L1: Biotinylated PD-1 binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
Request Protocol
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| 68Ga-Mirc415 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | 상세 | |
| IMGS-001 | IMGS-001 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Colorectal Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| CA-170 | CA-170; AUPM-170 | Phase 3 Clinical | Aurigene | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | 상세 |
| 89Zr-KN035(Wuxi No. 4 People's Hospital) | Clinical | Wuxi No. 4 People | Solid tumours | 상세 | |
| CTB-1 | CTB-1 | Clinical | GTS Biotech LLC | Neoplasms | 상세 |
| 68Ga-WL12 | [68Ga]WL12; 68Ga-WL12; 68Ga-WL-12 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | 상세 |
| 18F-WL12 | 18F-WL12; 18F-WL-12 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | 상세 |
| [68Ga]Ga-NOTA-RW102 | Clinical | Huashan Hospital | Carcinoma, Non-Small-Cell Lung | 상세 | |
| 68Ga-THP-APN09 | Clinical | Beijing Cancer Hospital | Lung Neoplasms | 상세 | |
| 18F-BMS-986192 | BMS-986192-[18F] | Clinical | Bristol-Myers Squibb Company | Neoplasms | 상세 |
| Durvalumab/Selumetinib sulfate | Phase 1 Clinical | Astrazeneca Plc | Neoplasms | 상세 | |
| Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) | Phase 1 Clinical | Jiangsu Huaiyu Pharmaceutical Co Ltd | Solid tumours | 상세 | |
| Garivulimab | BGB-A333 | Phase 1 Clinical | BeOne Medicines Ltd | Neoplasms; Solid tumours | 상세 |
| BJ-005 | BJ-005 | Phase 1 Clinical | Boji Biomedical Technology (Hangzhou) Co Ltd | Lymphoma; Solid tumours | 상세 |
| IBI-323(Innovent Biologics) | IBI-323 | Phase 1 Clinical | Neoplasms; Solid tumours | 상세 | |
| GNC-039 | GNC-039 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Glioma; Hematologic Neoplasms; Neoplasm Metastasis; Solid tumours | 상세 |
| SKB-337 | SKB337; A-337; SKB-337 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | 상세 |
| IMM2505 | IMM2505; IMM-2505 | Phase 1 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Solid tumours | 상세 |
| QLS31901 | QLS-31901; QLS31901 | Phase 1 Clinical | Qilu Pharmaceutical Co Ltd | Neoplasms | 상세 |
| Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Peritoneal Neoplasms; Pleural Effusion, Malignant | 상세 | |
| CCX-559 | CCX-559 | Phase 1 Clinical | Chemocentryx Inc | Neoplasms; Solid tumours | 상세 |
| Ragistomig | ABL-503; TJ-L14B/ABL503; ABL503; TJ-L14B | Phase 1 Clinical | I-Mab Biopharma Co Ltd | Solid tumours | 상세 |
| GS-19 | GT-90008; GS-19; GS-19-PLB-1C | Phase 1 Clinical | Gensun Biopharma Inc | Solid tumours | 상세 |
| TST-005 | TST-005; TST005 | Phase 1 Clinical | Suzhou Transcenta Therapeutics Co Ltd | Neoplasms; Papillomavirus Infections; Solid tumours | 상세 |
| BR-102 | BR102 | Phase 1 Clinical | Zhejiang BioRay Biopharmaceuticals Co Ltd | Neoplasms; Solid tumours | 상세 |
| AN-4005 | AN-4005 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Lymphoma; Neoplasms; Solid tumours | 상세 |
| PF-07257876 | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck | 상세 | |
| TT-00420/Atezolizumab | Phase 1 Clinical | TransThera Sciences (Nanjing) Inc | Gastrointestinal Neoplasms | 상세 | |
| IMM-2520 | IMM-2520 | Phase 1 Clinical | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | 상세 | |
| FS222 mAb² (F-star Therapeutics) | FS-222 | Phase 1 Clinical | F-star Beta Ltd | Neoplasm Metastasis; Neoplasms; Solid tumours | 상세 |
| Recombinant oncolytic type II herpes simplex virus (Binhui Biopharmaceutical) | BS-006; oHSV2-BiTEs; oHSV2CD3-PD-L1 | Phase 1 Clinical | Wuhan Binhui Biotechnology Co Ltd | Melanoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | 상세 |
| CN-202 | CN-202 | Phase 1 Clinical | Curon Biopharmaceutical Ltd | Hematologic Neoplasms; Solid tumours | 상세 |
| SHS-009 | SHS-009; SH009; SH-009 | Phase 1 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Liver Neoplasms; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 상세 |
| Gallium [68Ga] Natan recombinant PD-L1 single domain antibody | SNA-002; 68Ga-NOTA-SNA002 | Phase 1 Clinical | Smartnuclide Biopharma | Contrast agents; Neoplasms; Solid tumours | 상세 |
| CHECKvacc | CF33-hNIS-antiPDL1 | Phase 1 Clinical | City Of Hope National Medical Center, Imugene Ltd | Breast Neoplasms; Metastatic breast cancer; Triple Negative Breast Neoplasms | 상세 |
| SG-1408 | SG-1408; SG1408 | Phase 1 Clinical | Hangzhou Shangjian Biotechnology Co Ltd | Solid tumours | 상세 |
| CS-23546 | CS-23546; CS23546 | Phase 1 Clinical | Shenzhen Chipscreen Biosciences Co Ltd | Immune System Diseases; Neoplasms | 상세 |
| BPI-371153 | BPI-371153 | Phase 1 Clinical | Betta Pharmaceuticals Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Lymphoma; Solid tumours | 상세 |
| ASC-61 | ASC-61 | Phase 1 Clinical | Ascletis Pharma Inc | Neoplasms; Solid tumours | 상세 |
| QL-415 | QL-415 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | 상세 |
| HS-10386 | HS-10386 | Phase 1 Clinical | Jiangsu Hansoh Pharmaceutical Group Co Ltd, Shanghai Hansoh Biomedical Co Ltd | Solid tumours | 상세 |
| HBM-9027 | HBM-9027; HBM9027 | Phase 1 Clinical | Harbour Biomed | Neoplasms; Solid tumours | 상세 |
| Ori-Bs-001 | Ori-Bs-001 | Phase 1 Clinical | OriCell Therapeutics Co Ltd | Solid tumours | 상세 |
| Dual-targeting VEGFR1 and PD-L1 CAR-T cells Therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Ascites; Serositis | 상세 | |
| RAD-203 | RAD-203 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Carcinoma, Non-Small-Cell Lung | 상세 |
| 177Lu-RAD204 | 177Lu-anti-PD-L1 sdAb; RAD-204; 177Lu-RAD204 | Phase 1 Clinical | Radiopharm Theranostics Ltd | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Mismatch Repair Deficient Cancer; Skin Melanoma; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | 상세 |
| AUR-106 | AUR-106 | Phase 1 Clinical | Aurigene Discovery Technologies Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colonic Neoplasms; Esophageal Neoplasms; Kidney Neoplasms; Neoplasms; Stomach Neoplasms | 상세 |
| Recombinant anti-PD-L1/TGF-β bifunctional fusion protein | Phase 1 Clinical | Hualan Genetic Engineering (Henan) Co Ltd | Solid tumours | 상세 | |
| B-901 | B-901; B901 | Phase 1 Clinical | FutureGen Biopharm (Beijing) Co Ltd | Solid tumours | 상세 |
| KM602 | KM602; KM-602; XZP-KM602 | Phase 1 Clinical | Xuanzhu (Shijiazhuang) Biotechnology Co Ltd | Solid tumours | 상세 |
| MAX-001 | MAX-001; MAX001 | Phase 1 Clinical | Inflamax Pharmaceuticals (Guangzhou) Co Ltd | Solid tumours | 상세 |
| ND-021 | ND-021; NM21-1480; CS-2006; CS2006 | Phase 1 Clinical | Cstone Pharmaceuticals, Numab Therapeutics Ag | Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Squamous Cell; Colorectal Neoplasms; Fallopian Tube Neoplasms; Neoplasms; Peritoneal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | 상세 |
| SM-2275 | SM-2275; SM2275 | Phase 1 Clinical | Zhuhai StarMab BioMed Technology Ltd | Solid tumours | 상세 |
| BAT-7205 | BAT7205; BAT-7205 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Neoplasm Metastasis; Solid tumours | 상세 |
| YL-222 | YL222; YL-222 | Phase 1 Clinical | MediLink Therapeutics Co Ltd | Solid tumours | 상세 |
| PMI-06 | PMI-06; PMI06; 18F-DK222; [18F]DK-222 | Phase 1 Clinical | Precision Molecular Inc | Carcinoma, Non-Small-Cell Lung | 상세 |
| A-337 (Klus Pharma) | A337 (Klus Pharma); A-337 (Klus Pharma) | Phase 1 Clinical | Klus Pharma Inc | Neoplasms | 상세 |
| LW-347 | LW-347 | Phase 1 Clinical | Shanghai Longwood Biopharmaceuticals Co Ltd | Neoplasms | 상세 |
| JSKN-022 | JSKN022; JSKN-022 | Phase 1 Clinical | Alphamab Oncology | Neoplasms; Solid tumours | 상세 |
| BHP-01 | BHP-01; BHP01; α-PD-L1/4-1BB DLL3 CAR-T | Phase 1 Clinical | Chengdu Brilliant Pharmaceutical Co Ltd | Small Cell Lung Carcinoma | 상세 |
| XB-628 | XB628 | Phase 1 Clinical | Exelixis Inc | Neoplasms; Solid tumours | 상세 |
| DCR-PDL1 | DCR-PDL1 | Phase 1 Clinical | Dicerna Pharmaceuticals Inc | Solid tumours | 상세 |
| Naptumomab estafenatox/Durvalumab | NTX-352 | Phase 1 Clinical | Neotx Therapeutics Ltd | Solid tumours | 상세 |
| BMS-986238 | BMS-986238 | Phase 1 Clinical | Bristol-Myers Squibb Belgium Sa | Lymphoma; Solid tumours | 상세 |
| PF-08046037 | PF-08046037; SGN-PDL1iT | Phase 1 Clinical | Pfizer Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Melanoma; Neoplasms; Squamous Cell Carcinoma of Head and Neck | 상세 |
| JSKN-027 | JSKN027; JSKN-027 | Phase 1 Clinical | Alphamab Oncology | Neoplasms; Solid tumours | 상세 |
| [18F]DK222 | [18F]DK-222; [18F]DK222 | Phase 1 Clinical | Sidney Kimmel Comprehensive Cancer Center | Carcinoma; Carcinoma, Non-Small-Cell Lung | 상세 |
| 68Ga-NOTA-WL12 | Phase 1 Clinical | Beijing Cancer Hospital | Carcinoma, Non-Small-Cell Lung | 상세 | |
| 188Re-NM-01 | 188Re-NM-01 | Phase 1 Clinical | Nanomab Technology Ltd | Lung Neoplasms | 상세 |
| VSV-02 | VSV-02 | Phase 1 Clinical | Joint Biosciences Ltd | Breast Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours | 상세 |
| Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 1 Clinical | Eli Lilly And Company | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lymphoma, Extranodal NK-T-Cell; Neoplasms; Small Cell Lung Carcinoma | 상세 |
| Pd-1-pik | Pd-1-pik | Phase 1 Clinical | Huashan Hospital Affiliated To Fudan University | Glioblastoma | 상세 |
| IBC-Ab002 | IBC-Ab002 | Phase 1 Clinical | ImmunoBrain Checkpoint Inc | Alzheimer Disease | 상세 |
| CTX-8371 | CTX-8371 | Phase 1 Clinical | Compass Therapeutics LLC | Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | 상세 |
| ABL-501 | ABL-501 | Phase 1 Clinical | Abl Bio Inc | Solid tumours | 상세 |
| IMGS-001 | IMGS-001 | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Colorectal Neoplasms; Neoplasms; Prostatic Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| PEC-QT | PEC-QT; VCTX-210 | Phase 1 Clinical | Crispr Therapeutics Ag, Viacyte Inc | Autoimmune Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 1; Endocrine System Diseases; Glucose Metabolism Disorders; Immune System Diseases; Metabolic Diseases | 상세 |
| Q-1801 | Q-1801; Q 1801 | Phase 1 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Solid tumours | 상세 |
| HLX-37 | HLX37; HLX-37 | Phase 1 Clinical | Shanghai Henlius Biotech Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasm Metastasis; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| QL-301 | QL-301 | Phase 1 Clinical | Qlsf Biotherapeutics Inc | Neoplasms | 상세 |
| Xirestomig | ATG-101; ATG101; YN051 | Phase 1 Clinical | The Origin Cell Technology Group Co Ltd | Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Solid tumours | 상세 |
| BH-3120 | BH-3120 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Solid tumours | 상세 |
| TS-1905 | TS-1905; LY-01019; BA-1201 | Phase 1 Clinical | Shandong Boan Biotechnology Co Ltd | Solid tumours | 상세 |
| CYTO-102 | CYTO-NK-102; CYTO-102; COH06 | Phase 1 Clinical | CytoImmune Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms | 상세 |
| EMB-09 | EMB-09 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hepatitis B, Chronic; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | 상세 |
| AN-8025 | AN-8025 | Phase 1 Clinical | Hangzhou Adlai Nortye Biopharma Co Ltd | Solid tumours | 상세 |
| LP-008 | LP-008 | Phase 1 Clinical | Lepu Biopharma Co Ltd | Solid tumours | 상세 |
| SIM-0237 | SIM-0237; SIM-237 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Solid tumours; Urinary Bladder Neoplasms | 상세 |
| AB-101 (Arbutus Biopharma) | AB-101 (Arbutus Biopharma) | Phase 1 Clinical | Arbutus Biopharma Corp | Hepatitis B; Hepatitis B, Chronic | 상세 |
| anti-PSMA/anti-PSCA CAR T-cell therapy PD-1 silent (Shanghai Unicar-Therapy Bio-medicine) | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Hormone-Resistant Prostate Neoplasms | 상세 | |
| anti-PD-L1 CSR T-cell therapy (Marino Biotechnology) | Phase 1 Clinical | Beijing Marino Biotechnology Co Ltd | Glioblastoma; Neoplasms | 상세 | |
| dual anti-HER2/anti-PD-L1 CAR T-cell therapy (Sichuan University) | Phase 1 Clinical | Sichuan University | Carcinoma, Non-Small-Cell Lung; Metastatic breast cancer; Ovarian Neoplasms; Peritoneal Neoplasms; Stomach Neoplasms | 상세 | |
| Simridarlimab | IBI-322; IBI322 | Phase 1 Clinical | Bone Marrow Neoplasms; Hematologic Neoplasms; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell; Neoplasms; Solid tumours | 상세 | |
| IMMH-010 | IMMH-010 | Phase 1 Clinical | Tianjin Chase Sun Pharmaceutical Co Ltd | Neoplasms; Solid tumours | 상세 |
| Opucolimab | HLX-20 | Phase 1 Clinical | Neoplasms; Solid tumours | 상세 | |
| INCB-086550 | INCB-086550; INCB-86550 | Phase 1 Clinical | Incyte Corp | Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Solid tumours | 상세 |
| MCLA-145 | MCLA-145 | Phase 1 Clinical | Incyte Corp, Merus Nv | Lymphoma, B-Cell; Neoplasms; Solid tumours | 상세 |
| LOR-S03 | CDX-527 | Phase 1 Clinical | Celldex Therapeutics | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | 상세 |
| SL-279252 | TAK-252; SL-279252 | Phase 1 Clinical | Shattuck Labs Inc, Takeda Pharmaceutical Co Ltd | Adenocarcinoma; Astrocytoma; Carcinoma, Basosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 상세 |
| Lodapolimab | LY-3300054 | Phase 1 Clinical | Eli Lilly And Company | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Microsatellite instability-high cancer; Neoplasms; Pancreatic Neoplasms; Skin Melanoma; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) | Z-CTLs | Phase 1 Clinical | Hunan Zhaotai Yongren Biotech Co Ltd | Carcinoma, Non-Small-Cell Lung | 상세 |
| Emdifen | Phase 1 Clinical | Chinese Academy Of Medical Sciences, Tianjin Chase Sun Pharmaceutical Co Ltd | Solid tumours | 상세 | |
| Lesabelimab | BC-003; ADG-104 | Phase 2 Clinical | Adagene (Suzhou) Ltd, Baifan Biotechnology (Shanghai) Co Ltd, Dragonboat Biopharmaceutical, Guilin Sanjin Pharmaceutical Co Ltd | Carcinoma, Renal Cell; Neoplasms; Penile Neoplasms; Urinary Bladder Neoplasms | 상세 |
| ABSK-043 | ABSK043 | Phase 2 Clinical | ABbisko Therapeutics Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Esophageal Neoplasms; Neoplasms; Sarcoma; Solid tumours | 상세 |
| PM-8003 | PM8003 | Phase 2 Clinical | Solid tumours | 상세 | |
| PM-1003 | PM1003 | Phase 2 Clinical | Solid tumours | 상세 | |
| Palverafusp alfa | IMM-2510; SYN-2510; AXN-2510 | Phase 2 Clinical | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Neoplasms; Sarcoma; Solid tumours; Triple Negative Breast Neoplasms | 상세 | |
| PD-L1 antibody combined with CTLA-4 antibody (Shanghai Zhongshan Hospital) | Phase 2 Clinical | Shanghai Zhongshan Hospital | Cholangiocarcinoma | 상세 | |
| HLX-301 | HLX-301 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Lymphoma; Neoplasm Metastasis; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | 상세 | |
| Q-1802 | Q-1802 | Phase 2 Clinical | Qure Biotechnology (Shanghai) Co Ltd | Esophageal Neoplasms; Gastrointestinal Neoplasms; Solid tumours | 상세 |
| 6MW-3211 | 6MW3211; 6MW-3211 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Carcinoma, Renal Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Lymphoma; Myelodysplastic Syndromes; Neoplasms | 상세 |
| Recombinant anti-PD-L1/TGF-β bispecific antibody | Y101D; Y-101D | Phase 2 Clinical | Wuhan Yzy Biopharma Co Ltd | Carcinoma, Hepatocellular; Pancreatic Neoplasms; Solid tumours | 상세 |
| Carrizumab | Phase 2 Clinical | Jiangsu Hengrui Medicine Co Ltd | Adenocarcinoma; Esophageal Neoplasms; Stomach Neoplasms | 상세 | |
| Nebratamig | GNC-035 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Solid tumours | 상세 |
| FH-2001 | FH-2001 | Phase 2 Clinical | Solid tumours | 상세 | |
| INCB-099280 | INCB-099280; INCB-99280 | Phase 2 Clinical | Incyte Corp Ltd | Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Mesothelioma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Nasopharyngeal Carcinoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms | 상세 |
| QLF31907 | QLF31907; QLF-31907 | Phase 2 Clinical | Qilu Pharmaceutical Co Ltd | Carcinoma, Transitional Cell; Lymphoma, Non-Hodgkin; Melanoma; Neoplasms; Solid tumours | 상세 |
| IBC-0966 | IBC-0966 | Phase 2 Clinical | Neoplasms | 상세 | |
| Opamtistomig | LBL-024; LBL024 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Carcinoma, Neuroendocrine; Melanoma; Neoplasms; Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| BAT-7104 | BAT-7104 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Neoplasms; Solid tumours | 상세 |
| BCD-106 | BCD-106 | Phase 2 Clinical | BIOCAD JSC | Solid tumours | 상세 |
| 706-3SBio | SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody | Phase 2 Clinical | 3sbio Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Composite Lymphoma; Digestive System Neoplasms; Esophageal Neoplasms; Lymphoma; Neoplasms; Solid tumours | 상세 |
| DR-30206 | DR-30206 | Phase 2 Clinical | Zhejiang Doer Biologics Corp | Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck | 상세 |
| PM-1022 | PM-1022 | Phase 2 Clinical | Neoplasms | 상세 | |
| HB-0028 | HB-0028 | Phase 2 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd | Solid tumours; Uterine Cervical Neoplasms | 상세 |
| 99mTc-NM-01 | 99mTc-NM-01 | Phase 2 Clinical | Nanomab Technology Ltd | Carcinoma, Non-Small-Cell Lung | 상세 |
| Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd, SystImmune | Arthritis, Rheumatoid; Central Nervous System Lymphoma; Lupus Erythematosus, Systemic; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Solid tumours | 상세 |
| AP-505 | AP-505; B1962; AP505 | Phase 2 Clinical | AP Biosciences Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Colorectal Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 상세 |
| 18F-BMS-986229 | 18F-BMS-986229; [18F]BMS-986229 | Phase 2 Clinical | Bristol-Myers Squibb International Corp, PeptiDream Inc | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Stomach Neoplasms | 상세 |
| 6MW-3511 | 6MW-3511 | Phase 2 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Neoplasms; Solid tumours | 상세 |
| AB-001 (Agastiya Biotech) | AB01 (Agastiya Biotech); AB001 (Agastiya Biotech); AB-01 (Agastiya Biotech) | Phase 2 Clinical | Agastiya Biotech LLC | Neoplasms | 상세 |
| HK-010 | HK-010; HK010 | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd, Hefei Hankemab Biotechnology Co Ltd | Neoplasms; Solid tumours | 상세 |
| LB-101 (Centessa Pharmaceuticals) | LB-101 (Centessa Pharmaceuticals); LB-101 Tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody | Phase 2 Clinical | Centessa Pharmaceuticals Plc | Solid tumours | 상세 |
| BPB-101 | BPB-101 | Phase 2 Clinical | Betta Pharmaceuticals Co Ltd | Solid tumours | 상세 |
| Pacmilimab | CX-072 | Phase 2 Clinical | Cytomx Therapeutics Inc | Breast Neoplasms; Lymphoma; Melanoma; Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| PRS-344 | PRS-344S095012; S-095012; S-95012; PRS-344/ONC0055; PRS-344; PRS-344/S095012 | Phase 2 Clinical | Pieris Pharmaceuticals Inc | Solid tumours | 상세 |
| MAX-80391 | MAX-80391; MAX-8 | Phase 2 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Solid tumours | 상세 |
| SPX-303 | SPX-303 | Phase 2 Clinical | SparX Biopharmaceutical Corp | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 상세 |
| JSKN-033 | JSKN033; JSKN-033; JSKN-003/Envafolimab | Phase 2 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | 상세 |
| SOA-101 | SOA-101; SOA101 | Phase 2 Clinical | Shine-On BioMedical Co Ltd | Brain Neoplasms; Breast Neoplasms; Lung Neoplasms; Mouth Neoplasms; Ovarian Neoplasms; Solid tumours | 상세 |
| CVL006 | CVL006; B006 | Phase 2 Clinical | Convalife (Shanghai) Co Ltd | Neoplasms; Solid tumours | 상세 |
| DB-1419 | DB-1419 | Phase 2 Clinical | Duality Biologics (Suzhou) Co Ltd | Solid tumours | 상세 |
| IBI-3014 | IBI3014; IBI-3014 | Phase 2 Clinical | Solid tumours | 상세 | |
| HY-05350 | HY-0005; HY-05350 | Phase 2 Clinical | Sichuan Huiyu Seacross Pharma Technology Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Mesothelioma; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours | 상세 |
| [18F]AlF-NOTA-PCP2 | 18F-AlF-NOTA-PCP2 | Phase 2 Clinical | Shandong First Medical University | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Glioblastoma; Squamous Cell Carcinoma of Head and Neck | 상세 |
| SKB-103 | SKB103; SKB-103 | Phase 2 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | 상세 |
| HB-0036 | HB-0036 | Phase 2 Clinical | HuaBo Biopharm Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | 상세 |
| AP-203 | AP-203; AP203 | Phase 2 Clinical | AP Biosciences Inc | Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | 상세 |
| Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) | LP-002 | Phase 2 Clinical | Taizhou Houde Aoke Technology Co Ltd | Carcinoma, Squamous Cell; Digestive System Neoplasms; Melanoma; Primary mediastinal B cell lymphoma; Small Cell Lung Carcinoma; Solid tumours | 상세 |
| Type 1 diabetes stem cell gene therapy (Altheia Science) | Phase 2 Clinical | Altheia Science Srl | Diabetes Mellitus, Type 1 | 상세 | |
| Danburstotug | STI-3031; STI-A1015; IMC-001 | Phase 2 Clinical | Sorrento Therapeutics Inc | Biliary Tract Neoplasms; Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Neoplasm Metastasis; Neoplasms; Solid tumours | 상세 |
| 89Zr-durvalumab | Phase 2 Clinical | Radboud University Nijmegen | Carcinoma, Non-Small-Cell Lung; Head and Neck Neoplasms | 상세 | |
| Evixapodlin | GS-4224; OX-4224 | Phase 2 Clinical | Gilead Sciences Inc | Carcinoma, Non-Small-Cell Lung; Solid tumours | 상세 |
| Betifisolimab | MSB-2311 | Phase 2 Clinical | Suzhou Transcenta Therapeutics Co Ltd | Solid tumours | 상세 |
| PM-8001 | 6MW3111; PM-8001 | Phase 2 Clinical | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Neoplasms; Solid tumours | 상세 | |
| PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) | Phase 2 Clinical | Changhai Hospital of Navy Medical University | Pancreatic Neoplasms | 상세 | |
| BMS-936559 | MDX-1105; BMS-936559 | Phase 2 Clinical | Bristol-Myers Squibb Company | Colonic Neoplasms; Colorectal Neoplasms; HIV Infections; Hodgkin Disease; Leukemia, Myelogenous, Chronic; Liver Neoplasms; Lymphoma, Non-Hodgkin; Melanoma; Multiple Myeloma; Neoplasms; Rectal Neoplasms; Sepsis; Shock, Septic; Small Cell Lung Carcinoma | 상세 |
| Cadapersen | RG-6084; RO-7191863 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Hepatitis B; Hepatitis B, Chronic | 상세 |
| Vudalimab | XmAb-717; XmAb-20717; XmAb 717 | Phase 2 Clinical | Xencor Inc | Adenocarcinoma, Clear Cell; Adenoma, Acidophil; Adnexal Diseases; Astrocytoma; Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Basal Cell; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Castration-Sensitive Prostate Neoplasms; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Melanoma; Mesothelioma; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymoma; Thyroid Neoplasms; Uterine Cervical Neoplasms; Vulvar Neoplasms | 상세 |
| Durvalumab/Gefitinib | Phase 2 Clinical | Medimmune | Carcinoma, Non-Small-Cell Lung | 상세 | |
| RC-98 | RC-98; RC98; RC98-ADC | Phase 2 Clinical | Solid tumours; Stomach Neoplasms | 상세 | |
| PD-L1 t-haNK cell therapy | Phase 2 Clinical | Nantkwest Inc | Esophageal Neoplasms; Glioblastoma; Head and Neck Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | 상세 | |
| 89Zr-DFO-Atezolizumab | 89Zr-DFO-Atezolizumab | Phase 2 Clinical | University of Texas Southwestern Medical Center | Carcinoma, Renal Cell; Diagnostic agents; Lymphoma, B-Cell | 상세 |
| MAX-10181 | MAX-1; MAX-10181; MX-10181 | Phase 2 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Glioblastoma; Glioma; Neoplasms; Solid tumours | 상세 |
| FAZ-053 | FAZ-053; LAE-005; LAE005 | Phase 2 Clinical | Novartis Pharma Ag | Chordoma; Sarcoma, Alveolar Soft Part; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| Pumitamig | PM-8002; BMS-986545; PM8002; BNT-327 | Phase 3 Clinical | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Glioblastoma; Glioma; Liver Neoplasms; Lung Neoplasms; Mesothelioma; Metastatic breast cancer; Neoplasms; Neuroendocrine Tumors; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | 상세 | |
| HL-301 | HL-301 | Phase 3 Clinical | Hanmi Pharmaceutical Co Ltd | Acute Bronchitis; Lung Neoplasms; Pulmonary Disease, Chronic Obstructive; Radiation Pneumonitis | 상세 |
| Sotiburafusp alfa | HB0025; HB-0025 | Phase 3 Clinical | HuaBo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd, Zhejiang Huahai Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hematologic Neoplasms; Kidney Neoplasms; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| CA-170 | CA-170; AUPM-170 | Phase 3 Clinical | Aurigene | Carcinoma, Non-Small-Cell Lung; Neoplasms; Solid tumours | 상세 |
| SHS-006(Nanjing Sanhome Pharmaceutical) | SHS-006; SH-006; SH006 | Phase 3 Clinical | Nanjing Sanhome Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Liver Neoplasms; Solid tumours | 상세 |
| SGN-PDL1V | SGN-PDL1V; PF-08046054 | Phase 3 Clinical | Seagen Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Esophageal Squamous Cell Carcinoma; Pancreatic Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | 상세 |
| LB-1410 | LB-1410 | Phase 3 Clinical | L&L Biopharma Co Ltd | Lymphoma; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | 상세 |
| HLX-43 | HLX-43; HLX43 | Phase 3 Clinical | Shanghai Henlius Biotech Inc | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Nasopharyngeal Carcinoma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 상세 |
| Erfonrilimab | KN-046 | Phase 3 Clinical | Jiangsu Alphamab Biopharmaceuticals Co Ltd | Biliary Tract Neoplasms; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Lymphoma; Neuroendocrine Tumors; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms; Thymoma; Thymus Neoplasms; Triple Negative Breast Neoplasms | 상세 |
| Bintrafusp alfa | M-7824; GSK-4045154; MSB-0011359C | Phase 3 Clinical | Merck Serono | Anus Neoplasms; Biliary Tract Neoplasms; Brain metastases; Breast Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colonic Neoplasms; Colorectal Neoplasms; Esthesioneuroblastoma, Olfactory; Gallbladder Neoplasms; Ganglioglioma; Head and Neck Neoplasms; Hematologic Neoplasms; Intestinal Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Metastatic breast cancer; Microsatellite Instability; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Neoplasms; Neoplasms, Germ Cell and Embryonal; Nose Neoplasms; Oropharyngeal Neoplasms; Pancreatic Neoplasms; Papillomavirus Infections; Penile Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Respiratory papillomatosis; Sarcoma; Sarcoma, Kaposi; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Thymic epithelial tumor; Thymoma; Thymus Neoplasms; Triple Negative Breast Neop | 상세 |
| PD-1 Inhibitor Therapy(Hunan Cancer Hospital) | Hunan Cancer Hospital | 상세 | |||
| Treprilimab | Clinical | Sun Yat-Sen University | Oropharyngeal Neoplasms | 상세 | |
| INSIX RA (Indus Biotech) | Clinical | Indus Biotech Pvt Ltd | Arthritis, Rheumatoid; Inflammation | 상세 | |
| 64Cu-DOTA-nivolumab (Bristol-Myers Squibb/Ono Pharmaceutical) | Clinical | Bristol-Myers Squibb Company, Ono Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Melanoma | 상세 | |
| PD-1 gene engineered T cell therapy(Meijesell Biotechnology) | Phase 1 Clinical | Chengdu Medgencell, West China Hospital Of Sichuan University | Carcinoma, Non-Small-Cell Lung | 상세 | |
| Rituximab/Paclitaxel | AR-160 | Phase 1 Clinical | Mayo Clinic | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | 상세 |
| PD-1 knockout engineered T cells (Anhui Kedgene Biotechnology) | Phase 1 Clinical | Anhui Korton Biological Technology Co Ltd | Carcinoma, Hepatocellular; Esophageal Neoplasms | 상세 | |
| STW204 | STW-204; AI025; AI-025 | Phase 1 Clinical | Suzhou Stainwei Biotech Inc | Neoplasms; Solid tumours | 상세 |
| MW-11 | MW-11; 9MW1111; 9-MW1111; 9MW-1111; 9-MW-1111 | Phase 1 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Breast Neoplasms; Solid tumours | 상세 |
| Recombinant humanized anti-PD-1 monoclonal antibody (Shanxi Wichida Bright Pharmaceutical) | Phase 1 Clinical | Shanxi Weiqidaguangming Pharmaceutical Co Ltd | Solid tumours | 상세 | |
| αPD1-MSLN-CAR T cell therapy (Shanghai Cell Therapy Group Co.,Ltd) | BZDS1901; BZDS-1901; BZD1901 | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Mesothelioma; Ovarian Neoplasms; Solid tumours | 상세 |
| VT1093 | VT1093; VT-1093 | Phase 1 Clinical | Beijing Weiyuan Likang Biotechnology Co Ltd | Solid tumours | 상세 |
| NWY-001(Biocytogen Pharmaceuticals) | NWY001(Biocytogen Pharmaceuticals); YH008; YH-008; NWY-001(Biocytogen Pharmaceuticals) | Phase 1 Clinical | Hematologic Neoplasms; Neoplasms; Solid tumours | 상세 | |
| IBI-319 | IBI-319 | Phase 1 Clinical | Neoplasms | 상세 | |
| GNR-051 | GNR-051 | Phase 1 Clinical | Generium Pharmaceuticals | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma | 상세 |
| JS-201 | JS-201 | Phase 1 Clinical | Shanghai Junshi Biosciences Co Ltd | Neoplasms | 상세 |
| PH-762 | PH-762; PH762-ACT; RXI 762-ACT; mPH-762; PH762-TME | Phase 1 Clinical | Phio Pharmaceuticals Corp | Breast Neoplasms; Carcinoma, Merkel Cell; Carcinoma, Squamous Cell; Colorectal Neoplasms; Genital Neoplasms, Female; Lung Neoplasms; Melanoma; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck; Urogenital Neoplasms | 상세 |
| IBI-321 | IBI-321 | Phase 1 Clinical | Neoplasms; Solid tumours | 상세 | |
| CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma | 상세 | |
| Anti-PD1/anti-TIM3 bispecific antibody (L&L vision biopharmaceuticals) | Bis-5 | Phase 1 Clinical | L&L Biopharma Co Ltd | Neoplasms; Solid tumours; Uterine Cervical Neoplasms | 상세 |
| SHR-1901 | SHR-1901 | Phase 1 Clinical | Suzhou Suncadia Biopharmaceuticals Co Ltd | Neoplasms | 상세 |
| Recombinant human anti-PD-1 monoclonal antibody(Hec Biological) | Phase 1 Clinical | Dongguan City Hec Biological Medicine Res And Development Co Ltd | Esophageal adenocarcinoma; Stomach Neoplasms | 상세 | |
| Latikafusp | AMG-256 | Phase 1 Clinical | Amgen Inc | Solid tumours | 상세 |
| 89Zr-N-sucDf-pembrolizumab | Phase 1 Clinical | Merck & Co Inc, Umcg The University Medical Center Groningen | Carcinoma, Non-Small-Cell Lung; Melanoma | 상세 | |
| AK-131 | AK-131 | Phase 1 Clinical | Neoplasms; Solid tumours | 상세 | |
| CDX-585 | CDX-585; BSI-585 | Phase 1 Clinical | Biosion Inc, Celldex Therapeutics | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Colorectal Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Solid tumours; Stomach Neoplasms | 상세 |
| ABBV-1882 | ABBV-1882 | Phase 1 Clinical | Abbvie Inc | HIV Infections | 상세 |
| Pegylated recombinant human granulocyte colony stimulating factor(Sun Yat-sen University) | Phase 1 Clinical | Sun Yat-Sen University | Hematologic Neoplasms; Nasopharyngeal Carcinoma | 상세 | |
| SOT-201 | SOT-201; SO C108; SO-C108 | Phase 1 Clinical | Sotio | Neoplasms; Solid tumours | 상세 |
| Sym-024 | Sym-024; S-95024 | Phase 1 Clinical | Symphogen A/S | Neoplasm Metastasis; Solid tumours | 상세 |
| KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours | 상세 |
| JNJ-67484703 | JNJ-67484703; JNJ-4703 | Phase 1 Clinical | Janssen Research & Development Llc | Arthritis, Rheumatoid | 상세 |
| BC008-1A | BC008-1A | Phase 1 Clinical | Sichuan Luzhou Buchang Biopharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Esophageal Neoplasms; Glioblastoma; Glioma; Solid tumours | 상세 |
| WTX-212 | WTX-212 | Phase 1 Clinical | Westlake Therapeutics | Hematologic Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours | 상세 |
| HBT-708 | HBT-708; SSGJ-708 | Phase 1 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 상세 |
| STW204/Gotistobart | AI-061 | Phase 1 Clinical | Oncoc4 Inc | Anus Neoplasms; Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Neoplasms; Fallopian Tube Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Ovarian Neoplasms; Peritoneal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 상세 |
| MAX-001 | MAX-001; MAX001 | Phase 1 Clinical | Inflamax Pharmaceuticals (Guangzhou) Co Ltd | Solid tumours | 상세 |
| TEV-56278 | TEV-56278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | Melanoma; Neoplasms; Solid tumours | 상세 |
| WTX-212A | WTX-212A; WTX212A | Phase 1 Clinical | Zhejiang University | Neoplasms; Solid tumours | 상세 |
| BAT-3306 | BAT3306; BAT-3306 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Carcinoma, Non-Small-Cell Lung | 상세 |
| Pembrolizumab Biosimilar(Sandoz) | GME-751; GME751 | Phase 1 Clinical | Sandoz | Carcinoma, Non-Small-Cell Lung; Melanoma | 상세 |
| BPT-567 | BPT-567 | Phase 1 Clinical | Bright Peak Therapeutics Inc | Neoplasms; Solid tumours | 상세 |
| PD 1-proIL-2v (Proviva Therapeutics) | PTX-912 | Phase 1 Clinical | Proviva Therapeutics Inc | Neoplasm Metastasis; Neoplasms; Solid tumours | 상세 |
| S-4321 | S-4321 | Phase 1 Clinical | Seismic Therapeutics Inc | Arthritis, Psoriatic; Arthritis, Rheumatoid; Autoimmune Diseases; Dermatitis, Atopic; Immune System Diseases; Lupus Erythematosus, Cutaneous; Psoriasis | 상세 |
| P-1801 | P-1801 | Phase 1 Clinical | PharmaEssentia Corp | Solid tumours | 상세 |
| BZE-2209 | BZE-2209; BZE2209; αPD1/CTLA4-MSLN-CAR T Cells | Phase 1 Clinical | Shanghai Cell Therapy Group Co Ltd | Solid tumours | 상세 |
| IMC-S118AI | IMC-S118AI | Phase 1 Clinical | Immunocore Holdings PLC | Diabetes Mellitus, Type 1 | 상세 |
| GB-268 | GB268 | Phase 1 Clinical | Genor Biopharma Co Ltd | Neoplasms; Solid tumours | 상세 |
| CD-001 | CD-001 | Phase 1 Clinical | CD (Suzhou) Biopharma Co Ltd | Head and Neck Neoplasms; Hematologic Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neoplasms; Solid tumours | 상세 |
| γδ T-PD-1 Ab Cells therapy(Changzhou No.2 People’S Hospital) | Phase 1 Clinical | Changzhou No.2 People’S Hospital | Meningioma; Solid tumours | 상세 | |
| SSGJ-709 | SSGJ-709; SSGJ709 | Phase 1 Clinical | Shenyang Sunshine Pharmaceutical Co Ltd | Neoplasms; Solid tumours | 상세 |
| TQB-2252 | TQB-2252; TQB2252 | Phase 1 Clinical | Chia Tai Tianqing (Guangzhou) Pharmaceutical Co Ltd | Neoplasms; Solid tumours | 상세 |
| MAQ-001 | MAQ-001 | Phase 1 Clinical | MabQuest SA | Solid tumours | 상세 |
| FP-008 (Fapon Biotech) | FP-008; FP008 | Phase 1 Clinical | Guangdong Fapon Biopharma Inc | Neoplasms; Solid tumours | 상세 |
| SA-1211 | SA-1211 | Phase 1 Clinical | Suzhou Siran Biotech Co Ltd | Hepatitis B; Hepatitis B, Chronic | 상세 |
| TEV-278 | TEV-278; TEV-‘278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | Neoplasms | 상세 |
| CTX-10726 | CTX-10726 | Phase 1 Clinical | Compass Therapeutics Inc | Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Endometrial Neoplasms; Esophageal Neoplasms; Solid tumours | 상세 |
| ONO-4915 | ONO-4915 | Phase 1 Clinical | Ono Pharmaceutical Co Ltd | Autoimmune Diseases | 상세 |
| JLM-019 | JLM-019 | Phase 1 Clinical | Jecho Biopharmaceuticals Co Ltd | Lymphoma; Solid tumours | 상세 |
| IBI-3026 | IBI3026; IBI-3026 | Phase 1 Clinical | Neoplasms; Solid tumours | 상세 | |
| KH-813 | KH813; KH-813 | Phase 1 Clinical | Chengdu Kanghong Biotechnologies Co Ltd | Carcinoma, Non-Small-Cell Lung | 상세 |
| Pembrolizumab biosimilar (Shanghai Hongcheng Pharma) | Phase 1 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Microsatellite instability-high cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 상세 | |
| Pembrolizumab biosimilar (Hualan Genetic Engineering) | Phase 1 Clinical | Hualan Ankang Biotechnology Co Ltd | Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 상세 | |
| HLX-18 | HLX-18; HLX18 | Phase 1 Clinical | Solid tumours | 상세 | |
| TQB-6457 | TQB-6457; TQB6457 | Phase 1 Clinical | Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co Ltd | Neoplasms | 상세 |
| Anti-PD1 armored CD19 CAR-T cells therapy (Topcel-KH Pharmaceutical) | Phase 1 Clinical | Jiangsu Topcel-KH Pharmaceutical Co Ltd | Lymphoma, Large B-Cell, Diffuse | 상세 | |
| Pembrolizumab biosimilar (Alvotech Swiss) | AVT32-DRL_PB | Phase 1 Clinical | Alvotech Swiss Ag | Melanoma | 상세 |
| Reozalimab | IBI-318; LY-3434172; LY3434172 | Phase 1 Clinical | Eli Lilly And Company | Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Lymphoma, Extranodal NK-T-Cell; Neoplasms; Small Cell Lung Carcinoma | 상세 |
| CTX-8371 | CTX-8371 | Phase 1 Clinical | Compass Therapeutics LLC | Carcinoma, Non-Small-Cell Lung; Hodgkin Disease; Melanoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | 상세 |
| HY-0007 | HY-0007 | Phase 1 Clinical | Sichuan Huiyu Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Lung Neoplasms; Melanoma; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours | 상세 |
| GS-0151 | GS-0151; MB-151 | Phase 1 Clinical | University Of Oxford | Arthritis, Rheumatoid; Autoimmune Diseases; Inflammation | 상세 |
| iCasp9M28z T cells | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Breast Neoplasms; Lung Neoplasms; Mesothelioma | 상세 | |
| rHSV-1-APD1 | YST-02 | Phase 1 Clinical | Xiamen University | Central Nervous System Neoplasms; Glioma; Neoplasms; Solid tumours | 상세 |
| MHC-001 | MHC-001 | Phase 1 Clinical | Sichuan University | Carcinoma, Non-Small-Cell Lung | 상세 |
| Sofusa anti-PD-1 | Phase 1 Clinical | Sorrento Therapeutics Inc | Lymphoma, T-Cell, Cutaneous | 상세 | |
| Yinkang-001 | Phase 1 Clinical | Yinkang Biopharma Inc. | Solid tumours | 상세 | |
| PD-1 antibody (Boehringer Ingelheim International) | Phase 1 Clinical | Boehringer Ingelheim International Gmbh | Immune System Diseases | 상세 | |
| engineered TILs expressing anti PD-1 antibody (Shanghai Cell Therapy Group/Shanghai Cell Therapy Research Institute) | PD1-TIL | Phase 1 Clinical | Shanghai Cell Therapy Research Institute | Glioblastoma | 상세 |
| triple anti-CD19 CAR T-cell therapy/PD-1 checkpoint inhibitor/IL-21 receptor agonist (CD (Suzhou) Biopharma/Chinese People's Liberation Army General Hospital/Chinese academy of sciences) | Phase 1 Clinical | Chinese Academy Of Sciences | Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | 상세 | |
| Taminadenant | NIR-178; PBF-509 | Phase 1 Clinical | Palobiofarma Sl | Carcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Head and Neck Neoplasms; Lymphoma, Large B-Cell, Diffuse; Melanoma; Ovarian Neoplasms; Pancreatic Neoplasms; Parkinson Disease; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| Nivolumab(Mabpharm) | CMAB8-19; CMAB-819 | Phase 1 Clinical | Sinomab Bioscience Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Squamous Cell Carcinoma of Head and Neck | 상세 |
| RB-0004 | RB-0004 | Phase 1 Clinical | Reyoung Pharmaceutical Co Ltd | Lymphoma; Solid tumours | 상세 |
| Besufetamig | ONO-4685 | Phase 1 Clinical | Merus Nv | Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, T-Cell; Plaque psoriasis | 상세 |
| Sym-021 | Sym-021; S-95016; Sym021 | Phase 1 Clinical | Symphogen A/S | Lymphoma; Neoplasm Metastasis; Solid tumours | 상세 |
| Izuralimab | XmAb-23104; XmAb-104 | Phase 1 Clinical | Xencor Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Nasopharyngeal Carcinoma; Pancreatic Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 상세 |
| EGFRvIII-directed CAR-T cell tharapy (Novartis/University of Pennsylvania) | LXF-821 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Glioblastoma | 상세 |
| Eciskafusp Alfa | RO-7284755; RG-6279; PD1-IL2v | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Solid tumours; Urinary Bladder Neoplasms | 상세 |
| CC-90006 | C-90006; CC-90006 | Phase 1 Clinical | Anaptysbio Inc | Autoimmune Diseases; Psoriasis | 상세 |
| Zeluvalimab | AMG-404 | Phase 1 Clinical | Amgen Inc | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prostatic Neoplasms, Castration-Resistant; Small Cell Lung Carcinoma; Solid tumours | 상세 |
| Fidasimtamab | IBI-315; BH-2950 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Neoplasms; Solid tumours | 상세 |
| SYN-125 | SYN-125 | Phase 1 Clinical | Synermore Biologics (Suzhou) Co Ltd | Carcinoma; Solid tumours | 상세 |
| GX-P1 | GX-P1; PD-L1 hyfc | Phase 1 Clinical | Gannex Pharma Co Ltd | Autoimmune Diseases; Rejection of organ transplantation | 상세 |
| Recombinant human PD-1 antibody herpes simplex virus | Phase 1 Clinical | Xiamen University, Yangsheng Tang Co Ltd | Brain metastases; Carcinoma, Hepatocellular; Central Nervous System Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Pancreatic Neoplasms; Solid tumours; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 상세 | |
| HX-009 | HX-009; HX009-II-02 | Phase 2 Clinical | Waterstone Hanxbio Pty Ltd | Bile Duct Neoplasms; Biliary Tract Neoplasms; Liver Neoplasms; Lymphoma; Melanoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | 상세 |
| Lipustobart | LZM-009 | Phase 2 Clinical | Livzon(Group) Pharmaceutical Factory | Carcinoma, Non-Small-Cell Lung; Solid tumours; Thymoma | 상세 |
| Spartalizumab | PDR-001 | Phase 2 Clinical | Novartis Pharma Ag | Adenocarcinoma; Adenocarcinoma of Lung; Anus Neoplasms; Bone Marrow Diseases; Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cholangiocarcinoma; Chordoma; Colorectal Neoplasms; Digestive System Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastrointestinal Stromal Tumors; Glioblastoma; Head and Neck Neoplasms; Hematologic Diseases; Kidney Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Melanoma; Mesothelioma; Metastatic breast cancer; Multiple Myeloma; Myelodysplastic Syndromes; Nasopharyngeal Carcinoma; Neoplasms; Neoplasms, Squamous Cell; Neuroendocrine Tumors; Ovarian Neoplasms; Pancreatic Neoplasms; Persistent Fetal Circulation Syndrome; Polycythemia | 상세 |
| Acrixolimab | YBL-006; YBL 006 | Phase 2 Clinical | Y-biologics Inc | Solid tumours | 상세 |
| EMB-02 | EMB-02 | Phase 2 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours | 상세 |
| LBL-015 | LBL-015 | Phase 2 Clinical | Nanjing Leadsbiolabs Co Ltd | Neoplasms; Solid tumours | 상세 |
| Pradusinstobart | LVGN-3616; SSI-361 | Phase 2 Clinical | Lyvgen Biopharma(HK)Ltd | Carcinoma, Hepatocellular; Esophageal Neoplasms; Head and Neck Neoplasms; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Papillomavirus Infections; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uveal melanoma | 상세 |
| SSGJ-705 | SSGJ-705; 705 | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Neoplasms; Solid tumours | 상세 |
| Pidilizumab | MDV-9300; CT-011 | Phase 2 Clinical | Curetech Ltd | Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colonic Neoplasms; Colorectal Neoplasms; Hepatitis C, Chronic; Lymphoma; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Melanoma; Multiple Myeloma; Ovarian Neoplasms; Pancreatic Neoplasms; Primary mediastinal B cell lymphoma; Prostatic Neoplasms; Sarcoma | 상세 |
| 706-3SBio | SSGJ-706; 706 anti -PD1/PD -L1 BsAb; 706 anti-PD1/PD-L1 Bispecific antibody | Phase 2 Clinical | 3sbio Inc | Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Composite Lymphoma; Digestive System Neoplasms; Esophageal Neoplasms; Lymphoma; Neoplasms; Solid tumours | 상세 |
| Rosnilimab | ANB-030 | Phase 2 Clinical | Anaptysbio Inc | Alopecia Areata; Arthritis, Rheumatoid; Colitis, Ulcerative | 상세 |
| IAP-0971 | IAP-0971 | Phase 2 Clinical | SunHo (China) BioPharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Hepatitis B, Chronic; Neoplasms; Solid tumours; Urinary Bladder Neoplasms | 상세 |
| AK-129 | AK-129 | Phase 2 Clinical | Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 상세 | |
| HerinCAR-PD1 | Phase 2 Clinical | Ningbo Cancer Hospital | Meningitis, Fungal; Neoplasms; Solid tumours | 상세 | |
| Anti-CTLA-4/PD-1 expressing EGFR-CAR-T | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Solid tumours | 상세 | |
| EBV-specific TCR-T cell with anti-PD1 auto-secreted element | Phase 2 Clinical | Tcrcure Biopharma Ltd | Squamous Cell Carcinoma of Head and Neck | 상세 | |
| Peramprizumab | Phase 2 Clinical | Sun Yat-Sen University | Nasopharyngeal Carcinoma | 상세 | |
| TC-N201(TCRCure) | TC-N201 | Phase 2 Clinical | Tcrcure Biopharma Ltd | Neoplasms; Solid tumours | 상세 |
| SV-102 | SV-102; SV102; SYNC-T SV-102 | Phase 2 Clinical | Syncromune Inc | Prostatic Neoplasms, Castration-Resistant | 상세 |
| SAR-445877 | SAR-445877; KD-050; mut-1N-IL-15/38B2; SAR-877 | Phase 2 Clinical | Kadmon Corporation Llc | Carcinoma, Non-Small-Cell Lung; Solid tumours | 상세 |
| OSE-279 | OSE-279 | Phase 2 Clinical | Ose Immunotherapeutics | Carcinoma, Non-Small-Cell Lung; Lymphoma; Solid tumours | 상세 |
| PD-1 Inhibitor Therapy (Gene Key Life) | Phase 2 Clinical | Beijing Gene Key Life Technology Co Ltd | Carcinoma, Hepatocellular | 상세 | |
| PD-1 Monoclonal Antibody(Sixth Affiliated Hospital Sun Yat-Sen University) | Phase 2 Clinical | Sixth Affiliated Hospital Sun Yat-Sen University | Colorectal Neoplasms; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasms | 상세 | |
| Recombinant humanized anti-PD-1 monoclonal antibody (Anhui Anke Biotechnology) | Phase 2 Clinical | Anhui Anke Biotechnology (Group) Co Ltd | Carcinoma, Transitional Cell; Esophageal Neoplasms; Lung Neoplasms; Lymphoma; Neoplasms; Triple Negative Breast Neoplasms | 상세 | |
| HC-010(Shanghai Hongcheng) | HC-010; HC010 | Phase 2 Clinical | Shanghai Hongcheng Pharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | 상세 |
| MHB-039-A | MHB039A; MHB-039-A | Phase 2 Clinical | Minghui Pharmaceutical (Hangzhou) Co Ltd | Breast Neoplasms; Lung Neoplasms; Neoplasms; Solid tumours | 상세 |
| PD-1 inhibitor therapy(Shanghai Chest Hospital) | Phase 2 Clinical | Shanghai Chest Hospital | Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma | 상세 | |
| Ezabenlimab | BI-754091 | Phase 2 Clinical | C.H. Boehringer Sohn Ag & Co. Kg | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Colonic Neoplasms; Colorectal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastrointestinal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Rectal Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Soft Tissue Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | 상세 |
| Recombinant human anti-PD-1 monoclonal antibody(CSPC Zhongqi Pharma) | Phase 2 Clinical | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Solid tumours | 상세 | |
| Anti-PD-1 Antibody(Jiangxi Provincial Cancer Hospital) | Phase 2 Clinical | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 상세 | |
| CS-2009 | CS-2009 | Phase 2 Clinical | Cstone Pharmaceuticals | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| LM-299 | LM299; LM-299 | Phase 2 Clinical | LaNova Medicines Ltd | Neoplasms; Solid tumours | 상세 |
| SCTB-41 | SCTB41; SCTB-41; SCT-B41 | Phase 2 Clinical | SinoCelltech Ltd | Carcinoma, Non-Small-Cell Lung; Solid tumours | 상세 |
| HY-07121 | HY-07121; HY07121 | Phase 2 Clinical | Sichuan Huiyu Seacross Pharma Technology Ltd | Solid tumours | 상세 |
| AI-081 | AI-081 | Phase 2 Clinical | Oncoc4 Inc | Solid tumours | 상세 |
| GenSci-120 | GenSci-120; GenSci120 | Phase 2 Clinical | Changchun GeneScience Pharmaceuticals Co Ltd | Arthritis, Rheumatoid; Autoimmune Diseases; Graft vs Host Disease; Inflammatory Bowel Diseases; Lupus Erythematosus, Systemic; Sjogren's Syndrome | 상세 |
| CR-001(crescent biopharma) | CR-001; PR-054 | Phase 2 Clinical | Crescent Biopharma Inc, Paragon Therapeutics Inc | Neoplasms; Solid tumours | 상세 |
| JMT-108 | JMT-108; JMT108 | Phase 2 Clinical | Shanghai Jmt-Bio Inc | Carcinoma, Non-Small-Cell Lung; Melanoma; Neoplasms; Small Cell Lung Carcinoma; Solid tumours | 상세 |
| BPT-958 | BPT-958; BPT958 | Phase 2 Clinical | Bright Peak Therapeutics Inc | Neoplasms | 상세 |
| BAT-7111 | BAT7111; BAT-7111 | Phase 2 Clinical | Bio-Thera Solutions Ltd | Solid tumours | 상세 |
| OTP-01 | OTP-01 | Phase 2 Clinical | Ottimo Pharma Ltd | Neoplasms; Solid tumours | 상세 |
| Apalulizumab | Phase 2 Clinical | Shanghai Rui Jin Hospital | Pancreatic Neoplasms | 상세 | |
| SYS-6090 | SYS6090; SYS-6090 | Phase 2 Clinical | Jushi Biopharmaceutical Co Ltd | Carcinoma, Non-Small-Cell Lung; Digestive System Neoplasms; Neoplasms; Small Cell Lung Carcinoma | 상세 |
| MVR-C5252 | C-5252; MVR-C5252; T-5 | Phase 2 Clinical | Immvira Co Ltd | Brain Neoplasms; Ganglioglioma; Glioblastoma; Glioma; Solid tumours | 상세 |
| Sabestomig | AZD-7789 | Phase 2 Clinical | AstraZeneca Ag | Carcinoma, Non-Small-Cell Lung; Gastroesophageal Junction Neoplasms; Hodgkin Disease; Neoplasm Metastasis; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms | 상세 |
| ASKG-915 | ASKG-915 | Phase 2 Clinical | Askgene Pharma | Colorectal Neoplasms; Neoplasms; Solid tumours | 상세 |
| AWT-020 | AWT020; AWT-020; JS213; JS-213 | Phase 2 Clinical | Anwita Biosciences Inc | Autoimmune Diseases of the Nervous System; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Solid tumours | 상세 |
| BCMA-PD1 CAR T cell therapy (General Hospital of the People's Liberation Army) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Multiple Myeloma | 상세 | |
| PD-1 inhibitor peptide (Aurigene) | Phase 2 Clinical | Aurigene Oncology Ltd | Colonic Neoplasms; Communicable Diseases; Inflammation | 상세 | |
| TY-101 | TY101; TY-101 | Phase 2 Clinical | Tayu Huaxia Biotech Medical Group Co Ltd | Lymphoma; Solid tumours | 상세 |
| Anti-CTLA-4 and PD-1 CAR-T cell therapy (Shanghai Cell Therapy Research Institute) | Phase 2 Clinical | Shanghai Cell Therapy Research Institute | Neoplasms | 상세 | |
| T-3011 | T-3 (ImmVira Pharma); MVR-T3011; T3011; MVR-T3011 IT; MVR-T3011 IV; B015; B-015 | Phase 2 Clinical | Immvira Co Ltd | Ascites; Breast Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colorectal Neoplasms; Endometrial Neoplasms; Esophageal Neoplasms; Head and Neck Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphoma; Melanoma; Mesothelioma; Neoplasms; Ovarian Neoplasms; Sarcoma; Skin Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Urinary Bladder Neoplasms | 상세 |
| Nilvanstomig | ZG-005 | Phase 2 Clinical | Gensun Biopharma Inc | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Gastrointestinal Neoplasms; Lymphoma; Nasopharyngeal Carcinoma; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms | 상세 |
| MiHA-loaded PD-L silenced DC vaccination (Radboud University) | Phase 2 Clinical | Radboud University Nijmegen | Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; Hematologic Neoplasms | 상세 | |
| Lomvastomig | RG-7769; RO-7121661; R07121661 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Carcinoma, Non-Small-Cell Lung; Esophageal Squamous Cell Carcinoma; Melanoma; Small Cell Lung Carcinoma; Solid tumours | 상세 |
| Peresolimab | LY-3462817 | Phase 2 Clinical | Eli Lilly And Company | Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Connective Tissue Diseases; Immune System Diseases; Joint Diseases; Musculoskeletal Diseases; Psoriasis; Rheumatic Diseases | 상세 |
| PD-1 knockout EBV-CTL (Nanjing Medical University) | Phase 2 Clinical | Nanjing Medical University | Hodgkin Disease; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Nasopharyngeal Neoplasms; Stomach Neoplasms | 상세 | |
| Lorigerlimab | MGD-019; AEX1344 | Phase 2 Clinical | Macrogenics Inc | Adenocarcinoma, Clear Cell; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Pancreatic Ductal; Carcinoma, Renal Cell; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Hormone-Resistant Prostate Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Clear Cell Carcinoma; Ovarian Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Rectal Neoplasms; Skin Melanoma; Solid tumours; Uterine Cervical Neoplasms | 상세 |
| Abazistobart | SSGJ-609A; SSGJ-609-A; 609-A | Phase 2 Clinical | Sunshine GuoJian Pharmaceutical (Shanghai) Co Ltd | Breast Neoplasms; Sarcoma; Solid tumours | 상세 |
| Danvilostomig | SI-B003 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Esophageal Neoplasms; Melanoma; Metastatic breast cancer; Nasopharyngeal Carcinoma; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 상세 |
| Tobemstomig | RO-7247669 | Phase 2 Clinical | F. Hoffmann-La Roche Ltd | Breast Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Squamous Cell Carcinoma; Liver Neoplasms; Melanoma; Solid tumours | 상세 |
| MAX-10181 | MAX-1; MAX-10181; MX-10181 | Phase 2 Clinical | MaxiNovel Pharmaceuticals Co Ltd | Glioblastoma; Glioma; Neoplasms; Solid tumours | 상세 |
| Pimivalimab | JTX-4014 | Phase 2 Clinical | Jounce Therapeutics Inc | Carcinoma, Non-Small-Cell Lung; Neoplasms | 상세 |
| dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | 상세 |
| PE0105 | PE-0105 | Phase 2 Clinical | Shanghai Yunyi Health Technology Development Co Ltd | Neoplasms; Solid tumours | 상세 |
| Nivolumab biosimilar (Shandong Boan Biotechnology) | LY-01015; BA-1104 | Phase 3 Clinical | Shandong Boan Biotechnology Co Ltd | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal adenocarcinoma; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Glioma; Liver Neoplasms; Melanoma; Mesothelioma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Urinary Bladder Neoplasms | 상세 |
| RC-148 | RC-148 | Phase 3 Clinical | Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Metastatic breast cancer; Solid tumours; Stomach Neoplasms | 상세 | |
| Mavezelimab/Pembrolizumab | MK-4280A; MK-4820A | Phase 3 Clinical | Merck Sharp & Dohme Corp | Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Endometrial Neoplasms; Hodgkin Disease; Neoplasm Metastasis; Small Cell Lung Carcinoma; Solid tumours | 상세 |
| Pembrolizumab/Quavonlimab | MK-1308A | Phase 3 Clinical | Merck Sharp & Dohme Corp, Msd Ireland (Carlow), MSD R&D(China)Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Small Cell Lung Carcinoma; Solid tumours | 상세 |
| Rilvegostomig | AZD-2936 | Phase 3 Clinical | Astrazeneca Plc | Adenocarcinoma of Lung; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Merkel Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cholangiocarcinoma; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Melanoma; Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | 상세 |
| TQB-2868 | TQB-2868 | Phase 3 Clinical | Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group | Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Neoplasms; Pancreatic Neoplasms; Uterine Cervical Neoplasms | 상세 |
| Pembrolizumab/Vibostolimab | MK-7684A | Phase 3 Clinical | Merck & Co Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gallbladder Neoplasms; Hematologic Neoplasms; Lung Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 상세 |
| 707 (3SBio) | SSGJ707; SSGJ-707; 707; PF-08634404 | Phase 3 Clinical | 3sbio Inc | Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Colorectal Neoplasms; Digestive System Neoplasms; Endometrial Neoplasms; Esophageal adenocarcinoma; Gastroesophageal Junction Neoplasms; Kidney Neoplasms; Liver Neoplasms; Lung Diseases; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Stomach Neoplasms; Triple Negative Breast Neoplasms | 상세 |
| IBI-363 | IBI-363 | Phase 3 Clinical | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Gastroesophageal Junction Neoplasms; Lymphoma; Melanoma; Mucosal Melanoma; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 상세 | |
| Pembrolizumab biosimilar (biocad) | BCD-201 | Phase 3 Clinical | BIOCAD JSC | Carcinoma, Non-Small-Cell Lung; Melanoma; Skin Melanoma; Solid tumours | 상세 |
| INCA-33890 | INCA33890; INCA-33890 | Phase 3 Clinical | Incyte Corp | Colorectal Neoplasms; Ovarian Neoplasms; Solid tumours | 상세 |
| Nivolumab biosimilar(Amgen) | ABP-206 | Phase 3 Clinical | Amgen Inc | Melanoma | 상세 |
| Pembrolizumab biosimilar (Qilu) | QL2107; QL-2107 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Bile Duct Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Gastroesophageal Junction Neoplasms; Melanoma; Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | 상세 |
| PD-1 Inhibitor Therapy(Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University) | Phase 3 Clinical | Sun Yat-Sen Memorial Hospital Of Sun Yat-Sen University | Carcinoma, Hepatocellular; Rejection of liver transplantation; Squamous Cell Carcinoma of Head and Neck | 상세 | |
| Nivolumab biosimilar (Biocad) | BCD-263 | Phase 3 Clinical | BIOCAD JSC | Melanoma; Skin Melanoma | 상세 |
| Pembrolizumab biosimilar (Shanghai Henlius Biotech Inc) | HLX-17 | Phase 3 Clinical | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Melanoma; Solid tumours | 상세 | |
| SCTB-14 | SCTB-14; SCTB14 | Phase 3 Clinical | SinoCelltech Ltd | Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Nasopharyngeal Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck | 상세 |
| Pembrolizumab Biosimilar (Samsung Bioepis ) | SB27; SB-27 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Carcinoma, Non-Small-Cell Lung | 상세 |
| Pembrolizumab biosimilar(R-Pharm) | RPH-075 | Phase 3 Clinical | R-Pharm Jsc | Carcinoma, Non-Small-Cell Lung; Skin Melanoma; Squamous Cell Carcinoma of Head and Neck | 상세 |
| Pembrolizumab biosimilar (Laboratorio Elea Phoenix Sa) | MB-12; MB12 | Phase 3 Clinical | Laboratorio Elea Phoenix Sa | Carcinoma, Non-Small-Cell Lung | 상세 |
| Pembrolizumab biosimilar (Amgen) | ABP 234; ABP-234 | Phase 3 Clinical | Amgen Inc | Carcinoma, Non-Small-Cell Lung | 상세 |
| Pembrolizumab biosimilar (Celltrion) | CT-P51 | Phase 3 Clinical | Celltrion Inc | Carcinoma, Non-Small-Cell Lung; Lung Neoplasms; Melanoma; Stomach Neoplasms | 상세 |
| Atigotatug/Nivolumab | BMS-986489 | Phase 3 Clinical | Bristol-Myers Squibb Company | Small Cell Lung Carcinoma | 상세 |
| Nivolumab Biosimilar (Mabxience Research) | MB-11 (Mabxience Research); MB11 (Mabxience Research) | Phase 3 Clinical | Mabxience Research SL | Melanoma | 상세 |
| Rulonilimab | F-520 | Phase 3 Clinical | Shandong New Time Pharmaceutical Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Central Nervous System Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, T-Cell, Peripheral; Neoplasms; Solid tumours; Uterine Cervical Neoplasms | 상세 |
| JS-207 | JS-207 | Phase 3 Clinical | Dotbio Pte Ltd, Shanghai Junshi Biosciences Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Triple Negative Breast Neoplasms | 상세 |
| Tebotelimab | PD-1 X LAG-3; MGD-013 | Phase 3 Clinical | Macrogenics Inc | Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Endometrial Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Hematologic Neoplasms; Liver Neoplasms; Melanoma; Neoplasm Metastasis; Neoplasms; Ovarian Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 상세 |
| Nurulimab/Prolgolimab | BCD-217; BCD-145/BCD-100 | Phase 3 Clinical | BIOCAD JSC | Melanoma; Skin Melanoma | 상세 |
| Volrustomig | MEDI5752; MEDI-5752 | Phase 3 Clinical | Medimmune Llc | Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; Mesothelioma; Papillomavirus Infections; Sarcoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Uterine Cervical Neoplasms | 상세 |
| Genolimzumab | CBT-501; APL-501; APL501; GB226; GB-226 | Phase 3 Clinical | Apollomics Inc, Apollomics Inc, Genor Biopharma Co Ltd | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Hodgkin Disease; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell, Peripheral; Microsatellite Instability; Mismatch Repair Deficient Cancer; Neoplasms, Unknown Primary; Sarcoma, Alveolar Soft Part; Solid tumours; Thymoma; Thymus Neoplasms; Uterine Cervical Neoplasms | 상세 |
| BAT-1308 | BAT-1308 | Phase 3 Clinical | Bio-Thera Solutions Ltd | Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Uterine Cervical Neoplasms | 상세 |
| Nofazinlimab | CS-1003 | Phase 3 Clinical | Cstone Pharmaceuticals | Carcinoma, Hepatocellular; Lymphoma; Neoplasms; Solid tumours | 상세 |
| Iparomlimab | QL1604; QL-1604; PSB-103 | Phase 3 Clinical | Qilu Puget Sound Biotherapeutics Corp | Adenocarcinoma; Carcinoma, Hepatocellular; Esophageal Neoplasms; Gallbladder Neoplasms; Liver Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Uterine Cervical Neoplasms | 상세 |
| Cetrelimab | JNJ-63723283; JNJ-3283 | Phase 3 Clinical | Johnson & Johnson | Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Carcinoma, Transitional Cell; Hepatitis B, Chronic; Hormone-Sensitive Prostate Neoplasms; Melanoma; Multiple Myeloma; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Urinary Bladder Neoplasms | 상세 |
| Budigalimab | ABBV-181 | Phase 3 Clinical | Abbvie Inc | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Colorectal Neoplasms; Cystadenocarcinoma, Serous; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Head and Neck Neoplasms; HIV Infections; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Triple Negative Breast Neoplasms | 상세 |
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland
Email:order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521
주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호